https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28241 Wed 11 Apr 2018 10:43:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23398 Wed 11 Apr 2018 10:02:15 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23224 Thu 04 Nov 2021 10:40:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7448 Sat 24 Mar 2018 08:38:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11280 35 kg/m2) at baseline had more recurrences than those women with a low BMI (BMI < 23 kg/m2; adjusted hazard ratio [HR], 1.39; 95% CI, 1.06 to 1.82; Pheterogeneity = .03) and significantly more distant recurrences (adjusted HR, 1.46; 95% CI, 1.07 to 1.61; Pheterogeneity = .01). Overall, the relative benefit of anastrozole versus tamoxifen was nonsignificantly better in thin women compared to overweight women. Conclusion: These results confirm the poorer prognosis of obese women with early-stage breast cancer. Recurrence rates were lower for anastrozole than tamoxifen for all BMI quintiles. Our results suggest that the relative efficacy of anastrozole compared to tamoxifen is greater in thin postmenopausal women and higher doses or more complete inhibitors might be more effective in overweight women, but this requires independent confirmation.]]> Sat 24 Mar 2018 08:12:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11170 Sat 24 Mar 2018 08:10:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5363 Sat 24 Mar 2018 07:43:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45708 Fri 04 Nov 2022 10:18:27 AEDT ]]>